IE
MDNA

Israel Englander’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

Israel Englander’s Portfolio MDNA Stock Details MDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-24,988
Closed -$7.14K – 6820
2023
Q3 		$7.14K Buy
+24,988
New +$9.71K ﹤0.01% 5816
2023
Q2 		– Sell
-68,215
Closed -$44K – 6934
2023
Q1 		$44K Buy
68,215
+10,656
+19% +$6.64K ﹤0.01% 5664
2022
Q4 		$27K Buy
57,559
+45,379
+373% +$27.7K ﹤0.01% 5975
2022
Q3 		$10K Sell
12,180
-4,188
-26% -$4.73K ﹤0.01% 6668
2022
Q2 		$19K Buy
+16,368
New +$17.5K ﹤0.01% 6505
2021
Q2 		– Sell
-122,488
Closed -$500K – 7302
2021
Q1 		$500K Buy
+122,488
New +$499K ﹤0.01% 4826

Other funds holding MDNA

RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
NDSI
Newman Dignan & Sheerar Inc Providence, Rhode Island $523M AUM 26.16% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Israel Englander's MDNA Position: Q4 2023 in Review

Israel Englander sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q4 2023, closing a stake of 24,988 shares — an estimated $7.14K sold.

Israel Englander first reported a position in MDNA in Q1 2021 and held it in 6 quarters. The position peaked at $500K in Q1 2021. 3 funds tracked by Wall St. Rank hold MDNA as of Q4 2023.

  • Israel Englander reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q4 2023 after selling out during the quarter.
  • Israel Englander sold 24,988 Medicenna Therapeutics Corp. Common Shares shares in Q4 2023, an estimated $7.14K.
  • Israel Englander first reported a position in Medicenna Therapeutics Corp. Common Shares in Q1 2021 and held it in 6 quarters.
  • Israel Englander's Medicenna Therapeutics Corp. Common Shares position peaked at $500K in Q1 2021.
  • 3 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q4 2023.

Based on Millennium Management's 13F filing for Q4 2023, filed 14 Feb 2024.